North America Vagus Nerve Stimulation Devices Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

The North America vagus nerve stimulation devices market size is expected to reach US$ 1,187.8 million by 2033 from US$ 498.8 million in 2025. The market is estimated to record a CAGR of 11.5% from 2026 to 2033.

Executive Summary and North America Vagus Nerve Stimulation Devices Market Analysis:

The North America market for vagus nerve stimulation (VNS) devices is influenced by the growing trend of precision-oriented neuromodulation and the rising recognition of the role of bioelectronic medicine in clinical settings for neurological and psychiatric disorders. In contrast to earlier stages of adoption that were concerned primarily with refractory epilepsy, VNS devices are now being used for neuropsychiatric disorders as a multimodal treatment option, especially when dealing with challenging, resistant diseases. This reflects a proactive approach adopted by hospitals using VNS, where conventional drug therapies have proved ineffective.

Among the factors fueling market growth include high correlation between innovative research and implementation in the health care system in terms of specialty networks of neurologists and integrated hospitals which fast track research discoveries into clinical practice. The other major factor is the increased emphasis on decreasing drug dependence in the case of chronic neurological conditions which prompts medical professionals to adopt alternative therapeutic approaches such as device usage. Another area of improvement that favors the adoption of devices for neuromodulation therapy is the increased number of outpatient follow-up programs after device implantation, ensuring continuous use. On the other hand, adoption is hampered by a lack of procedure experience in small surgical units and a lack of insurance cover for new indications beyond epilepsy and depression. Adoption decisions in early-stage use of devices for psychiatric problems still suffer from a lack of data regarding the comparative performance of these products against drugs.

North America Vagus Nerve Stimulation Devices Market - Strategic Insights:

North America Vagus Nerve Stimulation Devices Market Segmentation Analysis:

Key segments that contributed to the derivation of the North America Vagus Nerve Stimulation Devices market analysis are product type, type, application, and end user.

• By product type, the vagus nerve stimulation devices market is segmented into implantable vagus nerve stimulators and external vagus nerve stimulators. The implantable vagus nerve stimulators segment dominated the market in 2025.
• Based on type, the vagus nerve stimulation devices market is classified into invasive and non-invasive devices. The invasive segment dominated the market in 2025.
• In terms of application, the vagus nerve stimulation devices market is categorized into pain & sensory modulation, functional disorders, cognitive & behavioral regulation, and other applications. The functional disorders segment dominated the market in 2025.
• On the basis of end user, the vagus nerve stimulation devices market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2025.

North America Vagus Nerve Stimulation Devices Market Drivers and Opportunities:

Growing Cases of Drug-Resistant Brain Disorders Worldwide

North America continues to face a rising clinical burden of drug-resistant neurological disorders, particularly refractory epilepsy, which remains a key driver for vagus nerve stimulation device adoption. In the United States, epilepsy affects millions of individuals, and a significant subset continues to experience seizures despite optimized anti-epileptic drug regimens. This persistent treatment gap has strengthened the role of neuromodulation therapies, including VNS, as an established option within advanced epilepsy management pathways.

The advanced healthcare infrastructure of the region facilitates an early diagnosis followed by stepwise treatment through medical devices. Amongst other things, the key role in identifying the candidates for the VNS therapy in North America belongs to the leading epilepsy centers operating in the United States and Canada (including the programs offered by top academic hospitals in North America). This task becomes possible due to clear clinical guidelines and referral systems that help promptly assess the eligibility for surgery and neuromodulation.

However, the rising incidence rate of neurological conditions in North America is not limited only to epilepsy. Chronic migraines, neurological problems associated with Parkinson‘s disease, and neurological dysfunction occurring as a consequence of stroke, are among the examples. Apart from the above reasons, growing pressure, age factors, and certain lifestyles are becoming the causes of neurobehavioral problems.

Broadening into New Therapeutic Applications

The North American vagus nerve stimulation devices market is rapidly expanding beyond epilepsy into a wide range of therapeutic applications. VNS therapy is increasingly being used for treatment-resistant depression, chronic migraine, and anxiety-related disorders, particularly in the United States, where mental health awareness and diagnosis rates are high. Clinical adoption is supported by established reimbursement pathways and growing physician familiarity with neuromodulation-based psychiatric care.

Moreover, non-invasive vagus nerve stimulation products have increasingly gained prominence within the region due to their applicability to an outpatient setting. The United States and Canada have seen the rising incorporation of neurostimulation wearable technology into telehealth and remote monitoring systems that ensure uninterrupted care delivery without requiring constant patient admission into hospitals. This follows the general trend of moving toward home-based treatments and personalized neurology care.

Further, increased research and development efforts within academic institutions and medical device firms are facilitating the rapid adoption of vagus nerve stimulation products. Clinical studies in North America have investigated the possibility of using VNS in treating inflammatory conditions, stroke recovery, and cognitive disorders. With leading centers of neuroscience research and considerable investments in neuromodulation innovation in place, VNS devices continue expanding their clinical applicability.

North America Vagus Nerve Stimulation Devices Market Size and Share Analysis:

The North America Vagus Nerve Stimulation Devices market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report evaluates important subsegments categorized within product type, type, application, and end user, highlighting their respective contributions to overall market performance.

By product type, the implantable vagus nerve stimulators subsegment dominated the market in 2025, driven by their established clinical efficacy and widespread adoption in the treatment of neurological and psychiatric disorders such as epilepsy and treatment-resistant depression. These devices provide continuous and targeted nerve stimulation, making them a preferred long-term therapeutic option for chronic conditions.

Based on type, the invasive subsegment dominated the market in 2025, owing to its higher clinical effectiveness and stronger therapeutic outcomes in managing severe and refractory conditions. Invasive vagus nerve stimulation systems are widely preferred in hospital-based settings due to their proven long-term benefits and consistent symptom control.

In terms of application, the functional disorders subsegment dominated the market in 2025, propelled by the increasing prevalence of conditions such as epilepsy and depression, along with growing clinical adoption of vagus nerve stimulation as an adjunct therapy for patients who are unresponsive to conventional treatments.

On the basis of end user, the hospitals subsegment dominated the market in 2025 due to the availability of advanced neurology infrastructure, specialized neurosurgical expertise, and comprehensive postoperative care required for implantation and management of vagus nerve stimulation devices.

North America Vagus Nerve Stimulation Devices Market Report Highlights:

North America Vagus Nerve Stimulation Devices Market Report Coverage and Deliverables:

The "North America Vagus Nerve Stimulation Devices Market Size and Forecast (2022-2033)" report provides a detailed analysis of the market covering below areas:

• Market size and forecast at regional and country levels for all market segments covered under the scope
• Market trends, as well as drivers, restraints, and opportunities
• Market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Market concentration, heat map analysis, prominent players, and recent developments for the Market
• Detailed company profiles, including SWOT analysis

North America Vagus Nerve Stimulation Devices Market Geographic Insights:

The geographical scope of the North America Vagus Nerve Stimulation Devices market report is divided into: The US, Canada, and Mexico. The US held the largest share in 2025.

The United States is leading the regional neuromodulation market owing to its highly fragmented but innovation-friendly ecosystem. Its competitive advantage is the presence of specialist epilepsy clinics, neurology departments in colleges, and integrated healthcare organizations that proactively contribute towards expanding applications for VNS treatment. Doctors in the US are more inclined to use stratified approaches to treatment, where VNS treatment is used on those patients who have not responded to other forms of treatment.

An interesting characteristic of the US market is the involvement of multi-disciplinary teams composed of neurologists, psychiatrists, and neurosurgeons, who make decisions collectively regarding a patient‘s candidacy for a VNS device. Moreover, there is an emerging trend of utilizing electronic monitoring devices in addition to implantable devices in order to maximize the therapeutic benefits of a procedure. Despite all this, there is great variability in VNS therapy adoption rates by different insurance and health delivery organizations. Although the level of skill and infrastructure for carrying out procedures is very high in the US, the availability of the treatment remains localized in certain parts of the country rather than spread throughout. Still, the US remains the leader when it comes to expanding the use of VNS therapies in North America.

North America Vagus Nerve Stimulation Devices Market Research Report Guidance:

• The report includes qualitative and quantitative data in the North America Vagus Nerve Stimulation Devices market across product type, type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the North America Vagus Nerve Stimulation Devices market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the North America Vagus Nerve Stimulation Devices market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the North America Vagus Nerve Stimulation Devices market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover North America Vagus Nerve Stimulation Devices market segments by product type, type, application, end user, and geography across The United States, Canada and Mexico. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the North America Vagus Nerve Stimulation Devices market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

North America Vagus Nerve Stimulation Devices Market News and Key Development:

The North America Vagus Nerve Stimulation Devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America Vagus Nerve Stimulation Devices market are:

• In July 2025, SetPoint Medical, announced that it received FDA approval for its implantable vagus nerve stimulation-based system for the treatment of rheumatoid arthritis, marking a major expansion of VNS therapy beyond neurological disorders into autoimmune disease management in the US.
• In January 2022, electroCore, announced that its gammaCore non-invasive vagus nerve stimulation (nVNS) device received FDA Breakthrough Device Designation for the treatment of post-traumatic stress disorder (PTSD), following clinical evidence showing significant symptom reduction compared to sham stimulation, strengthening its neuromodulation pipeline in the US market.

Key Sources Referred: